India to Guatemala: Acetaminophen Export Trade Route

To import finished pharmaceutical formulations containing Acetaminophen into Guatemala, compliance with the Ministry of Public Health and Social Assistance (MSPAS) regulations is mandatory. The Department of Regulation and Control of Pharmaceutical and Related Products (DRCPFA) oversees the registration and importation of pharmaceutical products.

Sanitary Registration:

All pharmaceutical products, including Acetaminophen formulations, must obtain a sanitary registration from the DRCPFA before importation and commercialization. The registration process involves submitting a comprehensive dossier that includes:

• Completed application forms (original and duplicate).
• Product composition and formula (common and scientific names).
• Valid foreign sanitary license (e.g., FDA or PAHO).
• Legalized trademark registration.
• Free Sale Certificate from the country of origin, certified by WHO or an equivalent authority.
• Monograph (if applicable for new products).
• Detailed product description.
• Product specifications and manufacturing standards.
• Description of analytical methods used.
• Packaging materials (samples required).
• Spanish-language labeling and instructions.
• Manufacturing contract (for maquila or toll production arrangements).
• Stability data (for products with a shelf life of 24 months or more).
• Product samples.
• Bioequivalence studies (if applicable).
• Specifications of active pharmaceutical ingredients (API) for new molecules.
• Copy of the sanitary license of the local distributor.

All documents in foreign languages must be officially translated into Spanish. The registration process can be bureaucratic, with potential delays extending over a year before approval. Sanitary registrations are valid for five years and must be renewed accordingly.

Import Permits:

In addition to sanitary registration, an import permit is required for each shipment. The DRCPFA issues these permits, and the process involves:

• Submitting a request through the Food and Medicine Window or the Psychotropic Drugs, Narcotics, Imports, and Exports Section, depending on the product classification.
• Providing necessary documentation, including the sanitary registration certificate, commercial invoice, and certificate of analysis.

The import permit process is regulated by Technical Standard Number 26, which outlines the procedure for issuing import authorizations. (latinalliance.co)

GMP Inspection Requirements:

Guatemala recognizes Good Manufacturing Practices (GMP) certifications issued by High Maturity and Performance Regulatory Authorities, as defined by the World Health Organization (WHO). Indian manufacturers exporting Acetaminophen formulations to Guatemala must provide a valid GMP certificate issued by the competent authority in India, such as the Central Drugs Standard Control Organization (CDSCO). This certificate must be duly legalized by Apostille for acceptance in Guatemala. (latinalliance.co)

Indian exporters of Acetaminophen formulations to Guatemala must adhere to stringent quality and GMP standards to ensure compliance with Guatemalan regulations.

GMP Certifications:

Manufacturers must hold a valid GMP certificate issued by the CDSCO or an equivalent authority. This certification confirms that the manufacturing facility complies with international GMP standards, ensuring the quality, safety, and efficacy of pharmaceutical products. The GMP certificate must be legalized by Apostille to be recognized by Guatemalan authorities. (latinalliance.co)

Approved Indian Facilities:

As of March 2026, specific information regarding Indian manufacturing facilities currently approved by the DRCPFA for exporting Acetaminophen formulations to Guatemala is not publicly available. Exporters are advised to consult directly with the DRCPFA or engage with local regulatory experts to obtain the most current information on approved facilities.

Recent Inspections and Regulatory Actions:

In May 2024, the DRCPFA issued an alert regarding the counterfeiting of Acetaminophen 120 mg/5mL syrup in Guatemala. The alert highlighted differences between the counterfeit and original products and urged healthcare professionals to take necessary precautions to avoid distributing counterfeit medicines. (latinalliance.co)

While this alert does not specifically target Indian exporters, it underscores the importance of maintaining stringent quality control measures and ensuring that all products comply with Guatemalan regulatory standards to prevent counterfeit incidents.

Between 2024 and 2026, several regulatory developments have impacted the importation of pharmaceutical products into Guatemala:

Counterfeit Alert (May 2024):

In May 2024, the DRCPFA issued a statement (Jef.DRCPFA-11-2024) alerting the public to the counterfeiting of Acetaminophen 120 mg/5mL syrup. The alert provided guidance on identifying counterfeit products and emphasized the risks associated with their distribution and use. (latinalliance.co)

Technical Standard 67 (October 2024):

In October 2024, the DRCPFA published Technical Standard 67, titled "Sanitary Registry of Reference for Biological and Biotechnological Products." This standard establishes the conditions and requirements for the authorization of biological and biotechnological products in Guatemala. While primarily focused on these product categories, the standard reinforces the importance of GMP certification and compliance with international regulatory standards for all pharmaceutical imports. (latinalliance.co)

Importation Procedures for Special Cases (April 2025):

In April 2025, the DRCPFA clarified procedures for the importation of pharmaceutical products in special cases, such as drugs for catastrophic, rare, or orphan diseases, and for human clinical research purposes. These procedures are outlined in Technical Standard Number 26 and involve specific requirements for obtaining import permits through designated DRCPFA sections. (latinalliance.co)

These developments highlight Guatemala's ongoing efforts to strengthen its pharmaceutical regulatory framework, emphasizing quality assurance, GMP compliance, and vigilance against counterfeit products.

In 2025, the over-the-counter (OTC) products market in Guatemala is projected to reach approximately USD 1.07 billion, with a compound annual growth rate (CAGR) of 4.36% from 2025 to 2029. Analgesics, including acetaminophen formulations, constitute a significant segment of this market. The demand for acetaminophen is driven by factors such as the prevalence of chronic diseases, an aging population, and increasing health awareness among consumers. Additionally, the market has seen a rise in the popularity of natural and herbal remedies, influencing consumer preferences. While specific data on domestic production versus imports of acetaminophen formulations are limited, Guatemala imports a substantial portion of its pharmaceutical products to meet domestic demand.

Guatemala adheres to the Central American Common Market (CACM) common external tariff schedule, which imposes import duties ranging from 0% to 15% on most goods. Finished pharmaceutical formulations under HS code 30049069 are subject to a 0% import duty rate, facilitating their importation without additional tariff burdens. There is no Free Trade Agreement (FTA) between India and Guatemala that affects pharmaceutical tariffs. Additionally, there are no known anti-dumping duties imposed on pharmaceutical imports from India into Guatemala.

In 2024, Guatemala's import market for acetaminophen formulations was supplied predominantly by Germany, Israel, India, Belgium, and the USA. The market exhibited a high concentration, indicating limited competition among suppliers. India's share of Guatemala's total acetaminophen formulation imports was relatively modest, accounting for approximately 0.2% of India's total exports of these products. Pricing dynamics among suppliers vary, with factors such as manufacturing costs, supply chain efficiencies, and regulatory compliance influencing the final prices of acetaminophen formulations in the Guatemalan market.

India has solidified its position as a global leader in the production of generic pharmaceuticals, supplying 20% of the worldwide demand for generic drugs as of 2024. This dominance is underpinned by a robust manufacturing infrastructure, with over 500 active pharmaceutical ingredient (API) producers contributing approximately 8% to the global API market. The country boasts 752 FDA-approved manufacturing facilities and 2,050 WHO Good Manufacturing Practices (GMP)-certified plants, ensuring high-quality production standards. These facilities are adept at producing a wide range of finished dosage forms, including tablets, capsules, syrups, and injections, with acetaminophen formulations being a significant component. India's cost-effective production methods, combined with a skilled workforce and supportive regulatory environment, enable the delivery of high-quality acetaminophen formulations at competitive prices.

In Q2 2025, the price of paracetamol (acetaminophen) in India was USD 2,958 per metric ton, compared to USD 3,732 in China and USD 3,767 in Germany. This pricing advantage positions India as a cost-effective source for acetaminophen formulations. Indian pharmaceutical products are recognized for their adherence to international quality standards, with numerous facilities holding FDA and WHO GMP certifications. Guatemala's regulatory authorities accept Indian-manufactured pharmaceuticals, facilitating smoother import processes. India's track record of reliable supply chains further enhances its appeal as a sourcing destination.

India's pharmaceutical industry has demonstrated consistent reliability in supplying acetaminophen formulations. The country's extensive manufacturing capacity, supported by a large number of FDA-approved and WHO GMP-certified facilities, ensures the ability to meet global demand. Advanced packaging and cold chain logistics capabilities further bolster the integrity of pharmaceutical products during transit. While occasional supply disruptions have occurred due to global events, India's proactive measures and robust infrastructure have minimized their impact. Leading manufacturers continue to invest in capacity expansion to meet increasing global demand.

For Guatemalan buyers seeking to source acetaminophen formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary among suppliers; negotiating favorable terms based on volume commitments can lead to cost advantages.

• Payment Terms: Standard payment terms in India-Guatemala pharmaceutical trade often include letters of credit or advance payments; establishing clear terms upfront is crucial.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits and compliance checks, to ensure suppliers meet international quality standards and regulatory requirements.

• Regulatory Compliance: Stay informed about both Indian and Guatemalan pharmaceutical regulations to ensure seamless importation and distribution of acetaminophen formulations.

By adhering to this comprehensive approach, Guatemalan companies can effectively qualify Indian suppliers of Acetaminophen formulations, ensuring product quality and regulatory compliance.